Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era
Pharmaceuticals · 25.03.2026 · 19 (4) · 529
DOI: 10.3390/ph19040529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.03.2026. Verfasst von Sema Seçilmiş und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation Center, Etlik City Hospital, Ankara 06170, Türkiye. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Allogeneic hematopoietic stem cell transplantation is associated with increased cardiovascular risk driven by endothelial dysfunction, chronic inflammation, and treatment-related metabolic disturbances, including dyslipidemia. In the contemporary era of post-transplant cyclophosphamide-based prophylaxis, the prognostic significance of dyslipidemia—particularly as assessed by non-HDL cholesterol—remains unclear. In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse, overall survival rates, and cardiovascular mortality in patients using myeloablative/reduced intensity conditioning regimens with post-transplant cyclophosphamide (PTCy) 50 mg/kg/day for 2 days in patients with acute leukemias.
Methods
A total of 95 adult patients with acute leukemias were included in their first remission who underwent matched sibling donor transplantation with PTCy (50 mg/kg on days +3 and +4). Patients were stratified according to pre-transplant non-HDL-C levels ( 0.05); cumulative incidences of grade II–IV aGVHD at +100 days, grade III–IV aGVHD at +100 days, and moderate-severe cGVHD at 1 year, relapse-free survival, and non-relapse mortality at 1 year were comparable in two cohorts (all p > 0.05). GVHD-free/relapse-free survival (GRFS) at 1 year was also comparable across groups (p = 0.15). Median GRFS was 150 (95% CI: 120–330) days and 270 (95% CI: 154-not reached) days, respectively [HR was 0.68 (0.40–1.15), p = 0.15; GRFS at 1 year was 66.6% vs. 52.0%, respectively]. The groups were also comparable in terms of overall survival (OS). Follow-up ranged from 0.5 to 108 months, and median follow-up was 60 months in two cohorts. Median OS was not reached in non-HDL-C < 160 (95% CI: 70 months–not reached) and 67 months in non-HDL-C ≥ 160 groups (95% CI: 13 months–not reached) (Log rank = 0.21). No cardiovascular death events occurred during the follow-up period.
Conclusions
In this homogeneous matched sibling donor transplant cohort with extended follow-up and uniform administration of post-transplant cyclophosphamide, cyclosporine-based GVHD prophylaxis, and anti-thymocyte lymphoglobulin (ATLG), pre-existing dyslipidemia was not associated with an adverse impact on GRFS, NRM, PFS, CMV reactivation, OS or long-term cardiovascular mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplantation Center, Etlik City Hospital, Ankara 06170, Türkiye.
- Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara 06200, Türkiye.
- Department of Internal Medicine, Division of Hematology, School of Medicine, Ankara Yıldırım Beyazıt University, Ankara 06760, Türkiye.
ORCID-Profile: Sema Seçilmiş, Burcu Aslan Candır, Mert Seyhan, Turgay Ulaş
Zitieren
APA
Seçilmiş, S., Aslan Candır, B., Hatipoğlu, U., Seyhan, M., Uncu Ulu, B., Yiğenoğlu, T. N., İskender, D., Kızıl Çakar, M., Ulaş, T., Dal, M. S., & Altuntaş, F. (2026). Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era. Pharmaceuticals, 19(4), 529. https://doi.org/10.3390/ph19040529
Vancouver
Seçilmiş S, Aslan Candır B, Hatipoğlu U, Seyhan M, Uncu Ulu B, Yiğenoğlu TN, et al. Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era. Pharmaceuticals. 2026;19(4):529. doi:10.3390/ph19040529
BibTeX
@article{Seilmi2026,
author = {Seçilmiş, Sema and Aslan Candır, Burcu and Hatipoğlu, Uğur and Seyhan, Mert and Uncu Ulu, Bahar and Yiğenoğlu, Tuğçe Nur and İskender, Dicle and Kızıl Çakar, Merih and Ulaş, Turgay and Dal, Mehmet Sinan and Altuntaş, Fevzi},
title = {Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {4},
pages = {529},
doi = {10.3390/ph19040529}
}
EUVIMED